
Pharmacally
CHMP
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in CHMP
Health TidingsCHMP May 2026 Roundup: EU Backs New Treatments Across Oncology, Obesity, and Rare DiseaseThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) delivered a wide‑ranging set of decisions at its May 2026 meeting.Fact-Checked
New Drug ApprovalCHMP April 2026 Roundup: Breakthroughs in SMA, MS, and Rare Metabolic DisordersThe CHMP April 2026 meeting resulted in positive opinions for four new therapies spanning multiple therapeutic areas, including a BTK inhibitor for multiple sclerosis, a gene therapy for…Fact-Checked
Health TidingsSanofi’s Sarclisa SC Gets CHMP Nod with OBI OptionCHMP recommends approval of Sarclisa SC for multiple myeloma, supported by Phase 3 IRAKLIA data showing non-inferiority to IV formulation and improved patient experience…Fact-Checked
New Drug ApprovalCHMP Recommends Five New Medicines for EU Approval in March 2026CHMP recommends five new medicines for EU approval, including novel therapies for bladder cancer, small cell lung cancer, rare immunodeficiency, and paediatric care, backed by strong clinical and…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.